Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Autor:	Marianne Pavel, Diego Ferone, Libuse Tauchmanovà, Fredrik Tiberg, Dieter Hörsch, Harald Lahner, Françoise Borson-Chazot, Håkan Olsson, Christelle Darstein, Rosario Pivonello, Anne Cailleux
Rok vydání:	2017
Předmět:	medicine.medical_specialty business.industry Depot Urology Octreotide medicine.disease Surgery law.invention Randomized controlled trial law Acromegaly medicine Ready to use In patient Open label Previously treated business medicine.drug
Zdroj:	Endocrine Abstracts.
ISSN:	1479-6848
DOI:	10.1530/endoabs.49.gp177
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::737df56cd615c484274e72b8b175b8cc https://doi.org/10.1530/endoabs.49.gp177 Zobrazit plný text záznamu